PRNewsWire
04 Mar 2026, 15:40 UTC · 29w ago
Verdict
Headline leans bearish. We score VTGN −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Vistagen's Phase 3 PALISADE-3 trial of fasedienol failed to meet its primary efficacy endpoint for the acute treatment of social anxiety disorder.
So whatFailure of a Phase 3 trial for a lead drug candidate is a catastrophic event for a biotech company's valuation and pipeline.
More negative than 99% of claims this week
Vistagen is facing a federal securities class action lawsuit alleging the company made false or misleading statements regarding the PALISADE-3 trial.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
Vistagen's stock price declined 80.27% to $0.86 following the announcement of the trial failure on December 17, 2025.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit following a failed Phase 3 clinical trial and an 80% drop in stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−55.7%
Price agrees with the score
$0.2703 vs $0.6100 close before publication (Mar 3) · not market-adjusted
VTGN chart →
